Search Result

Results for "

FFA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (4) COX (1) Free Fatty Acid Receptor (24) MMP (1) nAChR (1) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (2)
By Research Areas:	Cardiovascular Disease (6) Inflammation/Immunology (4) Metabolic Disease (30)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136896

FFA3 agonist 1	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
FFA3 agonist 1 is an agonist of free fatty acid receptor 3 (FFA3). FFA3 agonist 1 regulates the health effect of intestinal microbiota by activating FFA3 .

HY-15697

TUG-770 2 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-770 is a potent, selective and orally active *GPR40/FFA1* agonist with an EC₅₀ of 6 nM for human FFA1. TUG-770 shows a high selectivity for *FFA1* over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112813

TUG-1375 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-147987

FFA1 agonist-1	Free Fatty Acid Receptor	Metabolic Disease
FFA1 agonist-1 (Compound 17a) is an orally active fatty acid receptor 1 (FFA1) agonist with an EC₅₀ of 0.75 μM. FFA1 agonist-1 can be used for type 2 diabetes mellitus research .

HY-111143

SCH-900271	nAChR	Metabolic Disease
SCH-900271 is an orally active, potent nicotinic acid receptor (NAR) agonist with an EC₅₀ of 2 nM in the hu-GPR109a assay. SCH-900271 exhibits dose-dependent inhibition of plasma free fatty acid (FFA). SCH-900271 has an improved therapeutic window to flushing .

HY-160602

CPL207280

Free Fatty Acid Receptor Metabolic Disease

CPL207280 is an orally active GPR40/FFA1 agonist with anti-diabetic effects .

CPL207280	Free Fatty Acid Receptor	Metabolic Disease
CPL207280 is an orally active GPR40/FFA1 agonist with anti-diabetic effects .

HY-19996

AH-7614	Free Fatty Acid Receptor	Metabolic Disease
AH-7614 is a potent and selective FFA4 (GPR120) antagonist, with pIC₅₀s of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. AH-7614 has selectivity for FFA4 over FFA1 (pIC₅₀<4.6). AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid and the synthetic FFA4 agonist .

HY-12940

GLPG0974

5 Publications Verification

Free Fatty Acid Receptor Metabolic Disease

GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.
HY-116263

CATPB

1 Publications Verification

Free Fatty Acid Receptor Metabolic Disease

CATPB is a potent, selective free fatty acid receptor 2 (FFA2R/GPR43) antagonist .

GLPG0974 5 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

CATPB 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
CATPB is a potent, selective free fatty acid receptor 2 (FFA2R/GPR43) antagonist .

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-13467

AM-1638

1 Publications Verification

Free Fatty Acid Receptor Metabolic Disease

AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC₅₀ of 0.16 μM.

AM-1638 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AM-1638 is a potent and orally bioavailable *GPR40/FFA1* full agonist with an EC₅₀ of 0.16 μM.

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-100881

TUG-891 Maximum Cited Publications 6 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-891 is a potent and selective agonist for the long chain free fatty acid (LCFA) receptor 4 (FFA4/GPR120) .

HY-P1125

4-CMTB 2 Publications Verification	Free Fatty Acid Receptor	Others
4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC₅₀=6.38) .

HY-129136

TUG-1387

Others Others

TUG-1387 is a analog of both AH-7614 and TUG-1506 that has no activity at FFA4. TUG-1387 can serve as negative control for studies assessing FFA4 function.

TUG-1387	Others	Others
TUG-1387 is a analog of both AH-7614 and TUG-1506 that has no activity at FFA4. TUG-1387 can serve as negative control for studies assessing FFA4 function.

HY-129707

AMG 837 hemicalcium	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of *GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀* of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents .

HY-12940A

(S)-GLPG0974	Others	Metabolic Disease
(S)-GLPG0974 is the isomer of GLPG0974 (HY-12940), and can be used as an experimental control. GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13967B

AMG 837 calcium hydrate 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of *GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀* of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents . AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130120

HWL-088	Free Fatty Acid Receptor PPAR	Metabolic Disease
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC₅₀ of 18.9 nM) with moderate PPARδ activity (EC₅₀ of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .

HY-50162

GPR120 modulator 1	Free Fatty Acid Receptor	Metabolic Disease
GPR120 modulator 1 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F1. GPR120 modulator 1 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .

HY-50172

GPR120 modulator 2	Free Fatty Acid Receptor	Metabolic Disease
GPR120 modulator 2 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F13. GPR120 modulator 2 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Others	Metabolic Disease
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-103083

GPR40 agonist 4

Free Fatty Acid Receptor Metabolic Disease

GPR40 agonist 4 is a potent free fatty acid receptor 1 (FFA1/ GPR40) agonist with a pEC₅₀ of 7.54.

GPR40 agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 4 is a potent free fatty acid receptor 1 (FFA1/ GPR40) agonist with a pEC₅₀ of 7.54.

HY-114011

AMG7703	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
AMG7703 is a selective and allosteric agonists of *FFA2* (GPR43), the receptor for short-chain fatty acids (SCFAs), acetate, and propionate. AMG7703 can be used to research for in inflammatory and metabolic .

HY-121140

AZ1729	Free Fatty Acid Receptor	Metabolic Disease
AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in G_i-mediated pathways, but not at those transduced by G_q/G₁₁. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .

HY-B0283

Acipimox 1 Publications Verification K-9321	Others	Metabolic Disease
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-B0283A

Acipimox sodium K-9321 sodium	Others	Metabolic Disease
Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-148418

TUG-499	Free Fatty Acid Receptor	Metabolic Disease
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC₅₀ of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N1478

Gardenoside
Gardenoside is a natural compound found in Gardenia fruits, with hepatoprotective properties. Gardenoside suppresses the pain of chronic constriction injury by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Reactive Oxygen Species	Metabolic Disease
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-B0968

Trimetazidine dihydrochloride 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-B0968A

Trimetazidine 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-N8144

Niga-ichigoside F1	Others	Cardiovascular Disease
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-B0968S

Trimetazidine-d8 dihydrochloride	Autophagy	Cardiovascular Disease
Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-B0968R

Trimetazidine dihydrochloride (Standard)	Autophagy	Cardiovascular Disease
Trimetazidine (dihydrochloride) (Standard) is the analytical standard of Trimetazidine (dihydrochloride). This product is intended for research and analytical applications. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-121542

PPARδ agonist 10	PPAR	Metabolic Disease
PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC₅₀ values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .

HY-15589

GW9508 4 Publications Verification	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective *G protein-coupled receptors FFA1 (GPR40)* and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-114911

Feprazone DA2370; Prenazone; Zepelin	COX Reactive Oxygen Species MMP	Inflammation/Immunology
Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8144

Niga-ichigoside F1	Cardiovascular Disease Triterpenes Inula sericophylla Franch. Classification of Application Fields Terpenoids Labiatae Source classification Plants Disease Research Fields	Others
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Leguminosae Phenols Polyphenols Plants Sphaerophysa salsula	Others
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Structural Classification Albizia julibrissin Durazz. Leguminosae Source classification Plants Saccharides Monosaccharides	Reactive Oxygen Species
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

Cat. No.	Product Name	Chemical Structure

HY-B0968S

Trimetazidine-d8 dihydrochloride
Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

Trimetazidine-d8 dihydrochloride

Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks